Clinical Trials for Intellia Therapeutics

Explore 8 clinical trials worldwide

Showing 1-8 of 8 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Intellia Therapeutics

Clinical Trials (8)

NCT06634420
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
PHASE3Active, not recruiting
60 participants
Started: Jan 15, 2025 · Completed: Sep 30, 2027
1 condition1 sponsor31 locations
NCT06672237
A Phase 3 Study of NTLA-2001 in ATTRv-PN
PHASE3Recruiting
50 participants
Started: Nov 22, 2024 · Completed: Aug 31, 2028
20 conditions2 sponsors16 locations
NCT06379789
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
PHASE1/PHASE2Recruiting
130 participants
Started: Sep 11, 2024 · Completed: Dec 17, 2032
1 condition2 sponsors30 locations
NCT06262399
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
N/AEnrolling by invitation
100 participants
Started: Apr 12, 2024 · Completed: Apr 30, 2040
1 condition1 sponsor5 locations
NCT06128629
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
PHASE3Recruiting
765 participants
Started: Dec 13, 2023 · Completed: Apr 30, 2028
1 condition2 sponsors132 locations
NCT05697861
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
N/ARecruiting
72 participants
Started: Jul 10, 2023 · Completed: Mar 31, 2038
3 conditions1 sponsor4 locations
NCT05120830
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
PHASE1/PHASE2Active, not recruiting
37 participants
Started: Dec 10, 2021 · Completed: Mar 31, 2026
1 condition1 sponsor9 locations
NCT04601051
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
PHASE1Active, not recruiting
72 participants
Started: Nov 5, 2020 · Completed: Aug 31, 2026
3 conditions1 sponsor4 locations